logo

For the Inventor, By the Inventor

Evry, France

Genethon


USPTO Granted Patents = 54



Trademarks = 1

Forward Citations = 186

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Otto-Wilhelm Merten (10 out of 10 patents)

silverMedal Ana Maria Buj Bello (10 out of 11 patents)

bronzeMedal Federico Mingozzi (8 out of 15 patents)

4.  Isabelle Richard (8 out of 9 patents)

5.  Antoine Kichler (6 out of 8 patents)

6.  Giuseppe Ronzitti (5 out of 5 patents)

7.  Daniel Scherman (5 out of 38 patents)

8.  Monique Van Oers (5 out of 5 patents)

9.  Alan Beggs (5 out of 7 patents)

10.  Martin K Childers (5 out of 7 patents)

11.  Jean-Michel Rozet (5 out of 6 patents)

12.  Isabelle Perrault (5 out of 6 patents)

13.  Josseline Kaplan (5 out of 6 patents)

14.  Xavier Gerard (5 out of 6 patents)

15.  M Arnold Munnich (5 out of 5 patents)


Core Competencies:
Gene Therapy
AAV Vectors
Extracellular Vesicles
Hematopoietic Stem Cells
Dystrophic Muscle Pathologies
Baculovirus Expression Systems
Nucleotide Repeat Expansion Disorders
Muscular Dystrophy
Protein Expression
Gene Delivery
Systemic Treatment
Acid-alpha Glucosidase Variants

54 patents:

1. 12351816 - CNS gene delivery using peripheral administration of AAV vectors (2025-07-08),
2. 12305187 - Acid-alpha glucosidase variants and uses thereof (2025-05-20),
3. 12171843 - Hybrid regulatory elements (2024-12-24),
4. 12098355 - Fluid system for producing extracellular vesicles and related method (2024-09-24),
5. 12037362 - Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism (2024-07-16),
6. 12023366 - Efficient systemic treatment of dystrophic muscle pathologies (2024-07-02),
7. 12012613 - Genetically engineered hematopoietic stem cell as a platform for systemic protein expression (2024-06-18),
8. 11819478 - Selective gene therapy expression system (2023-11-21),
9. 11767538 - Widespread gene delivery to motor neurons using peripheral injection of AAV vectors (2023-09-26),
10. 11596698 - Synthetic polynucleotides encoding a human FKRP protein (2023-03-07),
11. 11564977 - Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) (2023-01-31),
12. 11541131 - Treatment of glycogen storage disease III (2023-01-03),
13. 11499154 - Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies (2022-11-15),
14. 11492621 - Methods for the treatment of Leber congenital amaurosis (2022-11-08),
15. 11427836 - Method for reducing the expression of NKCC1 in a subject (2022-08-30),
GENETHON is a non-profit research and development organization focused on gene therapy. They work towards finding curative solutions for rare genetic diseases. With a team of experts and state-of-the-art facilities, GENETHON conducts cutting-edge research, clinical trials, and supports promising projects in the field of gene therapy. Their ultimate goal is to improve the lives of patients affected by genetic diseases by developing safe and effective gene therapies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
54 Patents

#2 in Evry

#433 in France

#12,744 in the World

...
Evry, France

Genethon

Forward Citations = 186

61 inventors:

goldMedal Otto-Wilhelm Merten (10 out of 10 patents)

silverMedal Ana Maria Buj Bello (10 out of 11 patents)

bronzeMedal Federico Mingozzi (8 out of 15 patents)

4.  Isabelle Richard (8 out of 9 patents)

5.  Antoine Kichler (6 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…